Andre Turenne is President and Chief Executive Officer of Voyager Therapeutics, a leading company focused on gene therapy for severe neurological diseases. He previously served as Senior Vice President and Global Head of Business Development & Licensing at Sanofi. During his twelve years at Genzyme and Sanofi, Andre also held leadership roles in strategy and commercial operations, served as country General Manager in Australia/New Zealand and was a member of the Genzyme Executive Leadership Team. Earlier in his career, Andre worked as a strategy consultant. Andre holds an MBA from the Tuck School of Business at Dartmouth and a BA from Kalamazoo College.